Abstract
Background Tuberculosis is one of a major public health problem throughout the world. About 9.6 million people were estimated to have Tuberculosis in 2014. Out of this, 480 000 cases were multidrug-resistant Tuberculosis. Thus, it has to be identified, focused and prioritized for subsequent and targeted interventions. Therefore, the aim this study was to assess the prevalence and factors affecting adverse drug reaction among multidrug-resistant Tuberculosis patients.
Method Institution based retrospective cross sectional study design was included all patients with Multi Drug Resistant who were registered and treated from 9 January 2020 to 30 March 2020. Data abstraction form was used to obtain patient information from their cards. Data were collected by trained nurses who have been working at multidrug-resistant Tuberculosis treatment service. Data were entered, cleaned and checked using Epi Data version 4.6 statistical software and analyzed by SPSS version 23. Bivariate and multivariate logistic regression analyses were used to examine the association between independent and dependent variables. The results were presented as Odds Ratio with 95% CI.
Result A total of 286 patients were included in the study. The prevalence of adverse drug reaction in this study were 169 (59.1%). Factors such as Treatment outcome and comorbidity were significantly associated with adverse drug reaction among multidrug-resistant Tuberculosis patients.
Conclusion and Recommendation There was high prevalence of adverse drug reaction among multidrug-resistant Tuberculosis patients. Comorbidity and treatment outcome were the independent determinants. Patients who are identified with adverse drug events need special attention enhanced clinical management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance was obtained from the ethics Institutional Review Board of Addis Ababa University. A formal letter from Addis Ababa University was submitted to Saint Peters Tuberculosis Specialized Hospital and permission was obtained. Written informed consent for participation was not required for this study. To ensure confidentiality, name and other identifiers of the patients were not recorded on the data abstraction formats.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail address: FL:fikruletose6{at}gmail.com, DS:kergadegemu{at}gmail.com, HT:hawinetes{at}gmail.com, SA: sahleasfaw1919{at}gmail.com,
FL: MPH
DS: MPH
HT: MPH
SA: MPH
Data Availability
All data produced in the present study are available upon reasonable request to the authors.